aminocaproic acid has been researched along with Hyphema in 21 studies
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.
Hyphema: Bleeding in the anterior chamber of the eye.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the safety and efficacy of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema." | 9.10 | A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. ( Bradford, CA; Faulkner, A; Fekrat, S; Goldberg, MF; Juzych, M; McLeod, SD; Melia, M; Parker, JS; Pieramici, DJ; Rosen, R; Santander, SH, 2003) |
| "The purpose of this study is to determine the incidence of secondary hemorrhage after traumatic hyphema in children and to evaluate the efficacy of epsilon aminocaproic acid in reducing this incidence." | 9.08 | Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. ( Barsoum-Homsy, M; Brunette, I; Chevrette, L; Jacob, JL; Milot, J; Orquin, J; Polomeno, RC; Quigley, MG; Teboul, BK, 1995) |
| "To determine whether topically applied aminocaproic acid, like systemic aminocaproic acid, effectively reduces secondary hemorrhage after hyphemas and to compare the safety and effectiveness of topical application with those of systemic use and a control group." | 9.08 | Topical aminocaproic acid in the treatment of traumatic hyphema. ( Chames, M; Crouch, ER; Gray, MK; Williams, PB, 1997) |
| "Forty-nine patients, ages 3 to 18 years, who sustained nonpenetrating unilateral trauma with hyphemas were assigned randomly to receive either 100 mg/kg of epsilon-aminocaproic acid (EACA), an antifibrinolytic agent, orally every 4 hours for 5 days (maximum 30 g/day) or a placebo." | 9.06 | Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. ( Antoszyk, JH; Christianson, MD; Crawford, JS; Kraft, SP; Wagman, RD, 1987) |
| "Fifty-nine patients who sustained hyphema following blunt trauma were randomly assigned prospectively to either of two dose regimens of epsilon aminocaproic acid (Amicar)." | 9.06 | A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. ( Anderson, RJ; Fiscella, R; Frenkel, M; Goldberg, MF; Palmer, DJ, 1986) |
| "To report the characteristics and functional outcome of patients with traumatic hyphema and to discuss possible recommendations regarding the use of epsilon-aminocaproic acid." | 7.71 | Characteristics and functional outcome of traumatic hyphema without routine administration of epsilon-aminocaproic acid. ( Beiran, I; Miller, B; Talmon, T, 2002) |
| "Epsilon-aminocaproic acid (EACA) decreases rebleeding in traumatic hyphema through antifibrinolytic activity." | 7.68 | Factors affecting therapeutic concentration of topical aminocaproic acid in traumatic hyphema. ( Crouch, ER; Ehlers, WH; Riggs, PK; Williams, PB, 1990) |
| "Epsilon aminocaproic acid (EACA) is an antifibrinolytic agent currently used in the management of traumatic hyphema." | 7.68 | [Epsilon aminocaproic acid for management of traumatic hyphema with large blood clot in the anterior chamber]. ( Ashkenazi, I; Kotas, R; Neumann, D, 1990) |
| "We treated five patients receiving epsilon-aminocaproic acid who demonstrated sudden and accelerated clot dissolution with accompanying increases in intraocular pressure 24 to 96 hours after discontinuing treatment." | 7.67 | Intraocular pressure increase associated with epsilon-aminocaproic acid therapy for traumatic hyphema. ( Dieste, MC; Frambach, DA; Hersh, PS; Kylstra, JA; Larrison, WI; Shingleton, BJ, 1988) |
| "Systemically administered aminocaproic acid has been shown to reduce the incidence of secondary hemorrhage after traumatic hyphema." | 7.67 | Topical aminocaproic acid significantly reduces the incidence of secondary hemorrhage in traumatic hyphema in the rabbit model. ( Allingham, RR; Catlin, JC; Crouch, ER; Jacobson, J; Loewy, DM; Williams, PB, 1988) |
| " Although the evidence was limited, people with traumatic hyphema who receive aminocaproic acid or tranexamic acid are less likely to experience secondary hemorrhage." | 5.41 | Medical interventions for traumatic hyphema. ( Gharaibeh, A; Goldberg, MF; Lindsley, KB; Ng, SM; Scherer, RW; Woreta, FA, 2023) |
| "To determine the safety and efficacy of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema." | 5.10 | A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. ( Bradford, CA; Faulkner, A; Fekrat, S; Goldberg, MF; Juzych, M; McLeod, SD; Melia, M; Parker, JS; Pieramici, DJ; Rosen, R; Santander, SH, 2003) |
| "The purpose of this study is to determine the incidence of secondary hemorrhage after traumatic hyphema in children and to evaluate the efficacy of epsilon aminocaproic acid in reducing this incidence." | 5.08 | Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. ( Barsoum-Homsy, M; Brunette, I; Chevrette, L; Jacob, JL; Milot, J; Orquin, J; Polomeno, RC; Quigley, MG; Teboul, BK, 1995) |
| "To determine whether topically applied aminocaproic acid, like systemic aminocaproic acid, effectively reduces secondary hemorrhage after hyphemas and to compare the safety and effectiveness of topical application with those of systemic use and a control group." | 5.08 | Topical aminocaproic acid in the treatment of traumatic hyphema. ( Chames, M; Crouch, ER; Gray, MK; Williams, PB, 1997) |
| "Forty-nine patients, ages 3 to 18 years, who sustained nonpenetrating unilateral trauma with hyphemas were assigned randomly to receive either 100 mg/kg of epsilon-aminocaproic acid (EACA), an antifibrinolytic agent, orally every 4 hours for 5 days (maximum 30 g/day) or a placebo." | 5.06 | Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. ( Antoszyk, JH; Christianson, MD; Crawford, JS; Kraft, SP; Wagman, RD, 1987) |
| "Fifty-nine patients who sustained hyphema following blunt trauma were randomly assigned prospectively to either of two dose regimens of epsilon aminocaproic acid (Amicar)." | 5.06 | A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. ( Anderson, RJ; Fiscella, R; Frenkel, M; Goldberg, MF; Palmer, DJ, 1986) |
| " Although evidence was limited, it appears that people with traumatic hyphema who receive aminocaproic acid or tranexamic acid are less likely to experience secondary hemorrhaging." | 5.01 | Medical interventions for traumatic hyphema. ( Gharaibeh, A; Goldberg, MF; Lindsley, K; Savage, HI; Scherer, RW, 2019) |
| "To report the characteristics and functional outcome of patients with traumatic hyphema and to discuss possible recommendations regarding the use of epsilon-aminocaproic acid." | 3.71 | Characteristics and functional outcome of traumatic hyphema without routine administration of epsilon-aminocaproic acid. ( Beiran, I; Miller, B; Talmon, T, 2002) |
| "Epsilon-aminocaproic acid (EACA) decreases rebleeding in traumatic hyphema through antifibrinolytic activity." | 3.68 | Factors affecting therapeutic concentration of topical aminocaproic acid in traumatic hyphema. ( Crouch, ER; Ehlers, WH; Riggs, PK; Williams, PB, 1990) |
| "Epsilon aminocaproic acid (EACA) is an antifibrinolytic agent currently used in the management of traumatic hyphema." | 3.68 | [Epsilon aminocaproic acid for management of traumatic hyphema with large blood clot in the anterior chamber]. ( Ashkenazi, I; Kotas, R; Neumann, D, 1990) |
| "We treated five patients receiving epsilon-aminocaproic acid who demonstrated sudden and accelerated clot dissolution with accompanying increases in intraocular pressure 24 to 96 hours after discontinuing treatment." | 3.67 | Intraocular pressure increase associated with epsilon-aminocaproic acid therapy for traumatic hyphema. ( Dieste, MC; Frambach, DA; Hersh, PS; Kylstra, JA; Larrison, WI; Shingleton, BJ, 1988) |
| "Systemically administered aminocaproic acid has been shown to reduce the incidence of secondary hemorrhage after traumatic hyphema." | 3.67 | Topical aminocaproic acid significantly reduces the incidence of secondary hemorrhage in traumatic hyphema in the rabbit model. ( Allingham, RR; Catlin, JC; Crouch, ER; Jacobson, J; Loewy, DM; Williams, PB, 1988) |
| "An 18-year-old man with mild factor VIII deficiency developed hematuria and, subsequently, acute renal failure due to high-grade urinary obstruction by clots during therapy with cryoprecipitate, epsilon-aminocaproic acid, and acetazolamide administered for ocular trauma." | 3.67 | Acute renal failure due to high-grade obstruction following therapy with epsilon-aminocaproic acid. ( Bontempo, FA; Greenberg, A; Pitts, TO; Spero, JA, 1986) |
| " The contusion caused a recurrent hyphema which lasted approximately 6 weeks and responded to epsilon-aminocaproic acid treatment." | 3.66 | Recurrent traumatic hyphema due to increased local fibrinolysis. ( Barishak, R; Kaufman, S; Zehavi, H, 1980) |
| "Traumatic hyphema is the entry of blood into the anterior chamber (the space between the cornea and iris) subsequent to a blow or a projectile striking the eye." | 2.49 | Medical interventions for traumatic hyphema. ( Gharaibeh, A; Goldberg, MF; Lindsley, K; Savage, HI; Scherer, RW, 2013) |
| "Traumatic hyphema is the entry of blood into the anterior chamber (the space between the cornea and iris) subsequent to a blow or a projectile striking the eye." | 2.47 | Medical interventions for traumatic hyphema. ( Gharaibeh, A; Goldberg, MF; Lindsley, K; Savage, HI; Scherer, RW, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (38.10) | 18.7374 |
| 1990's | 6 (28.57) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Woreta, FA | 1 |
| Lindsley, KB | 1 |
| Gharaibeh, A | 4 |
| Ng, SM | 1 |
| Scherer, RW | 4 |
| Goldberg, MF | 7 |
| Savage, HI | 3 |
| Lindsley, K | 3 |
| Beiran, I | 1 |
| Talmon, T | 1 |
| Miller, B | 1 |
| Pieramici, DJ | 1 |
| Melia, M | 1 |
| Fekrat, S | 1 |
| Bradford, CA | 1 |
| Faulkner, A | 1 |
| Juzych, M | 1 |
| Parker, JS | 1 |
| McLeod, SD | 1 |
| Rosen, R | 1 |
| Santander, SH | 1 |
| Wilker, SC | 1 |
| Singh, A | 1 |
| Ellis, FJ | 1 |
| Zehavi, H | 1 |
| Kaufman, S | 1 |
| Barishak, R | 1 |
| Teboul, BK | 1 |
| Jacob, JL | 1 |
| Barsoum-Homsy, M | 1 |
| Brunette, I | 1 |
| Chevrette, L | 1 |
| Milot, J | 1 |
| Orquin, J | 1 |
| Polomeno, RC | 1 |
| Quigley, MG | 1 |
| Crouch, ER | 4 |
| Williams, PB | 3 |
| Gray, MK | 1 |
| Chames, M | 1 |
| Shiuey, Y | 1 |
| Lucarelli, MJ | 1 |
| Ehlers, WH | 1 |
| Riggs, PK | 1 |
| Kotas, R | 1 |
| Neumann, D | 1 |
| Ashkenazi, I | 1 |
| Javitt, JC | 1 |
| Romano, PE | 1 |
| Dieste, MC | 1 |
| Hersh, PS | 1 |
| Kylstra, JA | 1 |
| Larrison, WI | 1 |
| Frambach, DA | 1 |
| Shingleton, BJ | 1 |
| Allingham, RR | 1 |
| Catlin, JC | 1 |
| Loewy, DM | 1 |
| Jacobson, J | 1 |
| Kraft, SP | 1 |
| Christianson, MD | 1 |
| Crawford, JS | 1 |
| Wagman, RD | 1 |
| Antoszyk, JH | 1 |
| Pitts, TO | 1 |
| Spero, JA | 1 |
| Bontempo, FA | 1 |
| Greenberg, A | 1 |
| Palmer, DJ | 1 |
| Frenkel, M | 1 |
| Fiscella, R | 1 |
| Anderson, RJ | 1 |
4 reviews available for aminocaproic acid and Hyphema
| Article | Year |
|---|---|
Medical interventions for traumatic hyphema.
Topics: Adrenal Cortex Hormones; Aminocaproic Acid; Antifibrinolytic Agents; Aspirin; Glaucoma; Humans; Hyph | 2023 |
Medical interventions for traumatic hyphema.
Topics: Adrenal Cortex Hormones; Aminocaproic Acid; Antifibrinolytic Agents; Aspirin; Bandages; Bed Rest; Ch | 2019 |
Medical interventions for traumatic hyphema.
Topics: Adrenal Cortex Hormones; Aminocaproic Acid; Antifibrinolytic Agents; Aspirin; Bandages; Bed Rest; Es | 2013 |
Medical interventions for traumatic hyphema.
Topics: Adrenal Cortex Hormones; Aminocaproic Acid; Antifibrinolytic Agents; Aspirin; Bandages; Bed Rest; Es | 2011 |
5 trials available for aminocaproic acid and Hyphema
| Article | Year |
|---|---|
A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aminocaproic Acid; Anterior Chamber; Antifibrinoly | 2003 |
Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children.
Topics: Administration, Oral; Aminocaproic Acid; Antifibrinolytic Agents; Child; Double-Blind Method; Eye In | 1995 |
Topical aminocaproic acid in the treatment of traumatic hyphema.
Topics: Administration, Topical; Adult; Aminocaproic Acid; Anterior Eye Segment; Antifibrinolytic Agents; Do | 1997 |
Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid.
Topics: Adolescent; Adult; Aminocaproates; Aminocaproic Acid; Child; Child, Preschool; Clinical Trials as To | 1987 |
A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas.
Topics: Administration, Topical; Adolescent; Adrenal Cortex Hormones; Adult; Aminocaproates; Aminocaproic Ac | 1986 |
12 other studies available for aminocaproic acid and Hyphema
| Article | Year |
|---|---|
Characteristics and functional outcome of traumatic hyphema without routine administration of epsilon-aminocaproic acid.
Topics: Adolescent; Adult; Aminocaproic Acid; Antifibrinolytic Agents; Child; Eye Hemorrhage; Humans; Hyphem | 2002 |
Recurrent bleeding following traumatic hyphema due to mild hemophilia B (Christmas disease).
Topics: Aminocaproic Acid; Anterior Eye Segment; Antifibrinolytic Agents; Child; Eye Injuries; Hemophilia B; | 2007 |
Recurrent traumatic hyphema due to increased local fibrinolysis.
Topics: Adult; Aminocaproic Acid; Blood Coagulation Factors; Eye Injuries; Humans; Hyphema; Male; Recurrence | 1980 |
The treatment of traumatic hyphema with topical epsilon-aminocaproic acid.
Topics: Administration, Topical; Aminocaproic Acid; Anterior Eye Segment; Antifibrinolytic Agents; Eye Injur | 1997 |
Traumatic hyphema and patient outcomes--an oversight.
Topics: Ambulatory Care; Aminocaproic Acid; Anterior Eye Segment; Eye Injuries; Humans; Hyphema; Recurrence; | 1998 |
Factors affecting therapeutic concentration of topical aminocaproic acid in traumatic hyphema.
Topics: Acrylic Resins; Administration, Topical; Aminocaproic Acid; Animals; Aqueous Humor; Chromatography, | 1990 |
[Epsilon aminocaproic acid for management of traumatic hyphema with large blood clot in the anterior chamber].
Topics: Adult; Aminocaproic Acid; Contraindications; Eye Injuries; Humans; Hyphema | 1990 |
When does the failure to find a difference mean that there is none?
Topics: Adrenergic beta-Antagonists; Aminocaproic Acid; Blood Gas Monitoring, Transcutaneous; Clinical Trial | 1989 |
Intraocular pressure increase associated with traumatic epsilon-aminocaproic acid therapy for traumatic hyphema.
Topics: Aminocaproates; Aminocaproic Acid; Eye Injuries; Humans; Hyphema; Intraocular Pressure | 1989 |
Intraocular pressure increase associated with epsilon-aminocaproic acid therapy for traumatic hyphema.
Topics: Adolescent; Adult; Aminocaproates; Aminocaproic Acid; Anterior Chamber; Blood Coagulation; Erythrocy | 1988 |
Topical aminocaproic acid significantly reduces the incidence of secondary hemorrhage in traumatic hyphema in the rabbit model.
Topics: Acrylic Resins; Administration, Topical; Aminocaproates; Aminocaproic Acid; Animals; Corneal Injurie | 1988 |
Acute renal failure due to high-grade obstruction following therapy with epsilon-aminocaproic acid.
Topics: Acute Kidney Injury; Adolescent; Aminocaproates; Aminocaproic Acid; Blood Coagulation; Hematuria; He | 1986 |